Location History:
- Glasgow, GB (2011 - 2015)
- Newhouse, GB (2020)
- Lanarkshire, GB (2020 - 2023)
Company Filing History:
8 out of 9 
2 out of 99 
1 out of 5 Years Active: 2011-2023
Title: Joe Conner: Innovator in Oncolytic Virus Research
Introduction
Joe Conner is a prominent inventor based in Glasgow, GB. He has made significant contributions to the field of cancer treatment through his innovative research on oncolytic herpes simplex viruses. With a total of 9 patents to his name, Conner's work is paving the way for new therapeutic approaches in oncology.
Latest Patents
Among his latest patents, Conner has developed methods involving oncolytic herpes simplex virus infected cells. This invention discloses a monocyte, monocyte-derived cell, or macrophage infected with an oncolytic herpes simplex virus, along with its applications in treating diseases such as cancer. Another notable patent involves the use of oncolytic herpes simplex virus, either alone or in combination with immune checkpoint inhibitors, to treat cancer. This method includes administering doses of the virus to induce a Th1 immune response in patients, potentially enhancing the effectiveness of cancer therapies.
Career Highlights
Throughout his career, Joe Conner has worked with various organizations, including Virttu Biologics Limited and the University of Sheffield. His research has focused on harnessing the power of viruses to target and destroy cancer cells, showcasing his commitment to advancing medical science.
Collaborations
Conner has collaborated with notable colleagues in his field, including Susanne Moira Brown and Munitta Muthana. These partnerships have contributed to the development of innovative solutions in cancer treatment.
Conclusion
Joe Conner's work in the realm of oncolytic viruses represents a significant advancement in cancer therapy. His patents and research efforts are crucial in the ongoing battle against cancer, offering hope for more effective treatments in the future.